Additional file 2 of High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma

Additional file 2: Supplementary Fig. 1. Consort diagram. Supplementary Fig. 2. The extramedullary lesion of patient 14 (A), 11 (B) and 13 (C) before and 2 months after BCMA-CD38 CAR-T infusion.